{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/parkinsons-disease/background-information/complications/","result":{"pageContext":{"chapter":{"id":"8a05334f-9e7a-5662-b166-d86bd3c7546e","slug":"complications","fullItemName":"Complications","depth":2,"htmlHeader":"<!-- begin field 6d87696e-7370-4fd4-a011-e14deb359bf9 --><h2>What are the complications?</h2><!-- end field 6d87696e-7370-4fd4-a011-e14deb359bf9 -->","summary":"","htmlStringContent":"<!-- begin item 4bb47ad0-2bf6-4dfd-9d78-3030005b27b2 --><!-- begin field dea8849f-cb78-4826-a50e-aec8c70bd282 --><p><strong>People with Parkinson's disease may develop a range of motor and non-motor complications.</strong></p><ul><li><strong><a class=\"topic-reference internal-reference\" href=\"/topics/parkinsons-disease/background-information/complications/#motor-complications\">Motor complications</a></strong> — are usually related to the use of anti-parkinsonian medication (see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/parkinsons-disease/management/confirmed-parkinsons-disease/#specialist-management-of-motor-symptoms\">Specialist management of motor complications</a> for more information).<ul><li>Deteriorating function.</li><li>Loss of drug effect.</li><li>Motor fluctuations.</li><li>Dyskinesia.</li><li>Freezing of gait.</li><li>Falls.</li></ul></li><li><strong>Non-motor complications</strong> — these may be symptoms of Parkinson's disease, complications, or adverse effects of anti-parkinsonian medication. Most people are affected by non-motor problems in later Parkinson's disease.<ul><li><strong><a class=\"topic-reference internal-reference\" href=\"/topics/parkinsons-disease/background-information/complications/#mental-health-problems\">Mental health conditions</a>:</strong><ul><li>Depression, anxiety, and apathy.</li><li>Dementia and cognitive impairment.</li><li>Impulse control disorders and psychotic symptoms (delusions and hallucinations).</li></ul></li><li><strong><a class=\"topic-reference internal-reference\" href=\"/topics/parkinsons-disease/background-information/complications/#autonomic-dysfunction\">Autonomic dysfunction</a>:</strong><ul><li>Constipation.</li><li>Orthostatic hypotension.</li><li>Dysphagia and weight loss.</li><li>Excessive salivation and sweating.</li><li>Bladder and sexual problems.</li></ul></li><li><strong><a class=\"topic-reference internal-reference\" href=\"/topics/parkinsons-disease/background-information/complications/#other-complications\">Other complications</a>:</strong><ul><li>Nausea and vomiting.</li><li>Pain.</li><li>Sleep disturbance and daytime sleepiness.</li><li>Aspiration pneumonia.</li><li>Pressure sores.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">SIGN, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">Oertel, 2011a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">Oertel, 2011b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">Ferreira et al, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">Kalia, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">NICE, 2017</a>]</p><!-- end field dea8849f-cb78-4826-a50e-aec8c70bd282 --><!-- end item 4bb47ad0-2bf6-4dfd-9d78-3030005b27b2 -->","topic":{"id":"6cfe5031-c78a-5fcf-8597-8688ef0d3a41","topicId":"ac61656d-8e8b-48b8-bf1d-49f506afadb6","topicName":"Parkinson's disease","slug":"parkinsons-disease","lastRevised":"Last revised in February 2018","chapters":[{"id":"8bebf6b8-3a72-530a-ac48-52a8618f2267","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"044ab1d2-584c-5ed9-ab24-f7c8d64ef959","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"51b4e173-4f8a-5f7a-9e4a-fff68f32b031","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"29a7b8ce-d32b-5e9d-a682-56084e34b727","slug":"changes","fullItemName":"Changes"},{"id":"e1bb005f-8b49-5ae3-9670-a888d5def19a","slug":"update","fullItemName":"Update"}]},{"id":"fbbb2e6c-5309-5aa6-a27f-d6f508b6f994","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"40c62f24-40c5-5619-88aa-963a7de0d17d","slug":"goals","fullItemName":"Goals"},{"id":"2b0ddbc1-3535-545a-8be3-996ce778ee4d","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"a8f322a5-4ac1-50c9-8391-83584bd86b30","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d2a1f92e-43cd-575e-bcbd-7bd0e6792634","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e860c3e6-3288-5ee1-bd77-a6d4aa0c3006","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d3463e24-bbaa-5d3a-aca9-0d6da87a47f3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"644e166b-8434-55a7-859c-6479b609051a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"935e4ed2-12f3-5857-9a26-8a3beaed429c","slug":"definition","fullItemName":"Definition"},{"id":"58a49a4b-fb27-55f3-9afb-3c816842a76a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ce592a68-6b1f-5015-8125-2facfdcc4afe","slug":"prognosis","fullItemName":"Prognosis"},{"id":"8a05334f-9e7a-5662-b166-d86bd3c7546e","slug":"complications","fullItemName":"Complications"}]},{"id":"3951c9c0-49fe-5d17-8d1d-4c42b0b95c3f","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"e7662ffa-e42d-5bb5-9025-2ba5f6587a6f","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"435dc95c-73c1-5636-953b-feb3d7f82aaf","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"196d12bb-51bd-5a0b-872d-c7b60bde431b","fullItemName":"Management","slug":"management","subChapters":[{"id":"38b7e750-e77e-5791-a127-6e5192b69597","slug":"suspected-parkinsons-disease","fullItemName":"Scenario: Suspected Parkinson's disease"},{"id":"fae10e1b-26bc-523c-bc3b-ec45e56860ca","slug":"confirmed-parkinsons-disease","fullItemName":"Scenario: Confirmed Parkinson's disease"},{"id":"c0adefb6-a71d-5b3c-bc2d-b86a13219e16","slug":"end-stage-parkinsons-disease","fullItemName":"Scenario: End-stage Parkinson's disease"}]},{"id":"d811822d-b022-5b69-8514-00e15d349643","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"83038956-9818-52c8-9415-85ab073e43aa","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"757d939c-8a84-5a32-847b-38d850b38230","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"17a6cb12-1c93-5aff-bc74-2c2cee2f97ee","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bd851d10-0cce-5204-8b2e-54ae60c5767f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"9d232b23-7764-59d5-8026-50fff91a905b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7deed303-b70d-5459-8ca1-d40e9dbf3c88","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"1a717fd3-80b2-587f-8d46-3f904380d76a","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"644e166b-8434-55a7-859c-6479b609051a","slug":"background-information","fullItemName":"Background information"},"subChapters":[{"id":"934488c0-2bf5-5543-adca-cc5ee6859809","slug":"motor-complications","fullItemName":"Motor complications","depth":3,"htmlHeader":"<!-- begin field da27a688-f007-4001-b57c-b8c6fb9bf244 --><h3>Motor complications</h3><!-- end field da27a688-f007-4001-b57c-b8c6fb9bf244 -->","summary":null,"htmlStringContent":"<!-- begin item 813edc80-b6c5-48c0-8493-df466d82c1be --><!-- begin field 5c08efe5-5bab-449c-8408-2fdc9226a06d --><ul><li><strong>Motor complications (usually related to the use of anti-parkinsonian medication) include:</strong><ul><li><strong>Deteriorating function</strong> — immobility, slowness, withdrawal from activities, communication difficulties.</li><li><strong>Loss of drug effect</strong> — reduced efficacy of anti-parkinsonian medication over time.</li><li><strong>Motor fluctuations</strong><ul><li>End-of-dose fading (the benefit from levodopa wearing off before the next dose is due, usually predictable).</li><li>On-off phenomenon (rapid and unpredictable fluctuations between 'on' and 'off' periods, due to fluctuating responses to levodopa, usually after several years of use).</li><li>Dose failures — failure of anti-parkinsonian medication to provide symptom relief.</li></ul></li><li><strong>Dyskinesia</strong> (involuntary movements).<ul><li>Choreiform (quick fidgety movements).</li><li>Dystonic (slow, distorted movements and postures).</li></ul></li><li><strong>Freezing of gait</strong> — the inability to start or continue walking, characterized by difficulty in stepping forward (at initiation or during walking), and inability to lift the foot from the floor.</li><li><strong>Falls</strong><ul><li>Two-thirds of people with Parkinson's disease fall each year, and most people eventually fall, but early onset of falls may indicate an alternative cause of parkinsonism such as <a class=\"topic-reference internal-reference\" href=\"/topics/parkinsons-disease/diagnosis/differential-diagnosis/\">progressive supranuclear palsy</a>.</li><li>Falls are usually multifactorial, involving freezing of gait, postural instability, <a class=\"topic-reference internal-reference\" href=\"/topics/parkinsons-disease/background-information/complications/#autonomic-dysfunction\">orthostatic hypotension</a>, <a class=\"topic-reference internal-reference\" href=\"/topics/parkinsons-disease/management/confirmed-parkinsons-disease/#specialist-management-of-motor-symptoms\">drug treatments</a>, <a class=\"topic-reference internal-reference\" href=\"/topics/parkinsons-disease/management/confirmed-parkinsons-disease/#dementia-cognitive-impairment\">cognitive impairment</a>, and environmental factors.</li></ul></li><li><strong>Neuroleptic malignant syndrome</strong> — a rare, life-threatening idiosyncratic reaction which may occur if dopaminergic drugs are stopped abruptly in a person with Parkinson's disease.<ul><li>Symptoms include fever, altered mental state, muscle rigidity, and autonomic dysfunction.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">SIGN, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">Zesiewicz, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">Berman, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">Berardelli, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">Kalia, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">NICE, 2017</a>]</p><!-- end field 5c08efe5-5bab-449c-8408-2fdc9226a06d --><!-- end item 813edc80-b6c5-48c0-8493-df466d82c1be -->","subChapters":[]},{"id":"f6306719-0ed3-5063-bfd7-776d5f83b9b7","slug":"mental-health-problems","fullItemName":"Mental health problems","depth":3,"htmlHeader":"<!-- begin field d814aa33-45b3-48cc-bc55-5a314c61f315 --><h3>Mental health problems</h3><!-- end field d814aa33-45b3-48cc-bc55-5a314c61f315 -->","summary":null,"htmlStringContent":"<!-- begin item 831f57da-330c-4023-9c0f-98df9e6042c8 --><!-- begin field 10ad0915-5cb5-4a39-843e-7e5a1760fc30 --><ul><li><strong>Mental health problems include:</strong><ul><li><strong>Depression</strong><ul><li>This is very common in people with Parkinson's disease, and may affect up to 50% of people.</li><li>Depression may be underdiagnosed, as possible clinical features such as reduced facial expression, psychomotor slowing, sleep disturbance, weight loss, and cognitive impairment may overlap with those of Parkinson's disease itself. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/depression/\">Depression</a> for more information.</li></ul></li><li><strong>Anxiety</strong><ul><li>This may present as panic attacks, obsessive-compulsive behaviours, or generalized anxiety. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/generalized-anxiety-disorder/\">Generalized anxiety disorder</a> for more information.</li></ul></li><li><strong>Apathy</strong><ul><li>This may occur in the absence of depression or fatigue.</li></ul></li><li><strong>Dementia and cognitive impairment</strong><ul><li>About a third of people with Parkinson's disease have some cognitive impairment at diagnosis, and it is estimated that 24–31% of people with later Parkinson's disease have Parkinson's disease <a class=\"topic-reference internal-reference\" href=\"/topics/parkinsons-disease/management/confirmed-parkinsons-disease/#dementia-cognitive-impairment\">dementia</a>.</li><li>Parkinson's dementia is progressive and characterized by impairment of visuo-spatial abilities, impaired concentration, daytime sleepiness, visual hallucinations, and delusions.</li></ul></li><li><strong>Impulse control disorders</strong><ul><li>These are complex, compulsive, repetitive behaviours which affect 1–14% of people with Parkinson's disease, characterized by a failure to resist an impulse, drive, or temptation to perform an act that is harmful to the person or to others.</li><li>Features may include hypersexuality, compulsive gambling, binge eating, obsessive shopping, or punding (sterotyped behaviours such as repetitive assembling or collecting).</li><li>They may be an adverse effect of any dopaminergic <a class=\"topic-reference internal-reference\" href=\"/topics/parkinsons-disease/management/confirmed-parkinsons-disease/#specialist-management-of-motor-symptoms\">anti-parkinsonian medication</a>, and may be associated with overuse of dopamine agonist medication. They may develop at any stage in the course of Parkinson's disease.</li><li>Symptoms may not be reported by the person, and may be concealed.</li><li>People at increased risk include those on dopamine agonist therapy, those with a past history of impulsive behaviours, and those with a history of smoking and/or alcohol consumption.</li><li>They may lead to financial difficulties or criminal convictions.</li></ul></li><li><strong>Dopamine dysregulation syndrome</strong><ul><li>This is a rare syndrome which overlaps with impulse control disorders but is generally considered to be a distinct disorder.</li><li>It is defined as compulsive overuse of dopaminergic drugs (beyond that required for motor control), usually associated with punding, pathological gambling, or hypersexuality.</li><li>Symptoms may not be reported by the person, and may be concealed.</li><li>It may lead to financial difficulties or criminal convictions.</li></ul></li><li><strong>Psychotic symptoms (delusions and hallucinations)</strong><ul><li>These most commonly present with visual hallucinations in people with Parkinson's disease, and these occur in up to 40% of hospital-based patients taking dopaminergic drugs. Psychosis may also be caused by <a class=\"topic-reference internal-reference\" href=\"/topics/parkinsons-disease/management/confirmed-parkinsons-disease/#depression-anxiety\">depression</a> or <a class=\"topic-reference internal-reference\" href=\"/topics/parkinsons-disease/management/confirmed-parkinsons-disease/#dementia-cognitive-impairment\">dementia</a>.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">Alves et al, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">Chou, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">Lim et al, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">Wolters et al, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">SIGN, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">Kalia, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">NICE, 2017</a>]</p><!-- end field 10ad0915-5cb5-4a39-843e-7e5a1760fc30 --><!-- end item 831f57da-330c-4023-9c0f-98df9e6042c8 -->","subChapters":[]},{"id":"3f9c158d-6476-544f-8e47-126399641722","slug":"autonomic-dysfunction","fullItemName":"Autonomic dysfunction","depth":3,"htmlHeader":"<!-- begin field e6ae46e2-b0f8-484c-8290-818440f5ad46 --><h3>Autonomic dysfunction</h3><!-- end field e6ae46e2-b0f8-484c-8290-818440f5ad46 -->","summary":null,"htmlStringContent":"<!-- begin item 50becf5d-2810-4ea2-9075-ccfadee8b15c --><!-- begin field 313d98dc-3d21-466b-8d96-b1e4565e9957 --><ul><li><strong>Autonomic dysfunction may present as:</strong><ul><li><strong>Orthostatic hypotension</strong><ul><li>This occurs in at least 20% of people with Parkinson's disease, but may be asymptomatic.</li><li>Symptoms include fatigue, pre-syncope and syncope, falls, and gradual or sudden loss of consciousness.</li><li>It is defined as a decrease of 20 mmHg or more in systolic blood pressure and 10 mmHg or more in diastolic blood pressure within 3 minutes of being in the upright position.</li><li>The cause is thought to be Lewy body degeneration in the hypothalamus, brainstem, and peripheral nervous system. Anti-parkinsonian medication, other drugs, and comorbidities may also cause or exacerbate symptoms.</li></ul></li><li><strong>Dysphagia</strong><ul><li>Swallowing difficulties may affect up to 95% of people with Parkinson's disease, and usually relate to disease severity. </li><li>Dysphagia is important to identify and manage promptly, as it can increase the risk of asphyxiation, silent aspiration or aspiration pneumonia, malnutrition and dehydration, and difficulty taking oral medications.</li></ul></li><li><strong>Weight loss</strong><ul><li>Unintended weight loss occurs in over 50% of people with Parkinson's disease.</li><li>Causes may include moderate or severe dyskinesia, dysphagia, depression, and malnutrition related to Parkinson's disease; or other causes such as malignancy and endocrine disease.</li></ul></li><li><strong>Excessive salivation</strong><ul><li>Excessive salivation or drooling occurs in 70–80% of people with Parkinson's disease and may be more common in men.</li><li>It can lead to social embarrassment, soiling of clothing, and perioral infection.</li><li>It may result from oropharyngeal dysfunction, including reduced swallow frequency.</li></ul></li><li><strong>Excessive sweating</strong><ul><li>Severe sweating can occur as an end-of-dose 'off' phenomenon. It can also occur during the 'on' motor state, when it is usually associated with dyskinesia.</li></ul></li><li><strong>Bladder problems</strong><ul><li>Up to 75% of people with Parkinson's disease develop urinary symptoms. </li><li>Nocturia is a common and often early urinary symptom. Daytime urgency, frequency, and urge incontinence are also common.</li><li>Urinary incontinence is usually associated with detrusor overactivity and overactive bladder syndrome. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/incontinence-urinary-in-women/\">Incontinence - urinary, in women</a> for more information.</li></ul></li><li><strong>Sexual problems</strong><ul><li>Erectile dysfunction is more common in people with Parkinson's disease (affecting 60–70% or people) than in age-matched controls (38%). See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/erectile-dysfunction/\">Erectile dysfunction</a> for more information.</li><li>Men with Parkinson's disease may also experience sexual dissatisfaction and premature ejaculation.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/parkinsons-disease/management/confirmed-parkinsons-disease/#specialist-management-of-motor-symptoms\">Dopaminergic drugs</a> can also induce hypersexuality, even when there is erectile dysfunction.</li><li>In women, difficulties with arousal, low sexual desire, and anorgasmia are common.</li></ul></li><li><strong>Constipation</strong><ul><li>Up to 30% of people with Parkinson's disease have colonic dysmotility, and up to 60% have anorectal dysfunction.</li><li>Lewy body degeneration in the myenteric plexus of the colon leads to slow transit times and, occasionally, megacolon, intestinal pseudo-obstruction, and volvulus. A combination of disordered contraction and relaxation of the muscles of defecation, which may in part be dystonic, leads to excessive straining, pain, and a sense of incomplete evacuation.</li><li>Constipation can also be complicated by medication (such as dopamine agonist and antimuscarinic medication), and may also result from reduced fluid and fibre intake, and decreased mobility.</li><li>Faecal incontinence, if it occurs, is usually due to overflow around faecal impaction. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/constipation/\">Constipation</a> for more information.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">SIGN, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">Zesiewicz, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">Ferreira et al, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">British Dietetic Association, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">Kalia, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">NICE, 2017</a>]</p><!-- end field 313d98dc-3d21-466b-8d96-b1e4565e9957 --><!-- end item 50becf5d-2810-4ea2-9075-ccfadee8b15c -->","subChapters":[]},{"id":"9fd75eb1-c237-520b-8518-dcd37eeb4326","slug":"other-complications","fullItemName":"Other complications","depth":3,"htmlHeader":"<!-- begin field 5dba2c0e-9065-4cf4-a3f6-f99f42dc02b5 --><h3>Other complications</h3><!-- end field 5dba2c0e-9065-4cf4-a3f6-f99f42dc02b5 -->","summary":null,"htmlStringContent":"<!-- begin item 80db9afe-cf14-4f8c-987b-1232d80c2a1a --><!-- begin field 4510bea8-03c0-46e4-8bb3-b6aa8d98fcdf --><ul><li><strong>Other complications include:</strong><ul><li><strong>Nausea and vomiting</strong><ul><li>Nausea is a common adverse effect of all anti-parkinsonian medication, particularly at the start of treatment. Vomiting is rare. </li><li>In addition, about 16% of people with Parkinson's disease who are <em>not </em>taking dopaminergic medication experience nausea. </li></ul></li><li><strong>Pain</strong><ul><li>Pain occurs in up to 60% of people with Parkinson's disease, is more common in people with Parkinson's disease than in age-matched controls, may be multifactorial, and often worsens during the course of the disease.</li></ul><ul><li>Musculoskeletal pain — may be exacerbated by rigidity, stiffness, and immobility (such as frozen shoulder and contractures); may be associated with skeletal deformity, postural abnormalities, and antalgic gait. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/shoulder-pain/\">Shoulder pain</a> for more information.</li><li>Dystonic pain — associated with dystonic (twisting) movements and postures, which often occur in the feet in the 'off' period.</li><li>Radicular neuropathic pain — pain in the distribution of a nerve or root, associated with motor or sensory signs of nerve or root entrapment. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/neuropathic-pain-drug-treatment/\">Neuropathic pain - drug treatment</a> for more information.</li><li>Primary or central neuropathic pain — burning, tingling sensations not confined to a dermatome or root territory, which has no musculoskeletal or dystonic cause. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/neuropathic-pain-drug-treatment/\">Neuropathic pain - drug treatment</a> for more information.</li><li>Akathisia-related pain — caused by a feeling of restlessness leading to an inability to keep still.</li></ul></li><li><strong>Sleep disturbance</strong> — may be caused by:<ul><li>Degeneration of sleep regulation centres in the brainstem and thalamocortical pathway.</li><li>Restless legs syndrome. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/restless-legs-syndrome/\">Restless legs syndrome</a> for more information.</li><li>Nocturnal akinesia (inability to turn over in bed).</li><li>Nocturia.</li><li>Anxiety or depression.</li><li>Parkinson's disease dementia or other forms of dementia.</li><li>Vivid dreams, nightmares, or hallucinations related to anti-parkinsonian medication.</li><li>Rapid eye movement (REM) sleep behaviour disorder, characterized by abnormal or disruptive behaviours which occur during REM sleep and are often related to dream enactment. Examples include talking, laughing, shouting, gesturing, grabbing, punching, kicking, or sitting up in bed during sleep.</li></ul></li><li><strong>Daytime sleepiness</strong><ul><li>Excessive daytime sleepiness and dozing affects 15–54% of people with Parkinson's disease.</li><li>Causes include Parkinson's disease itself, poor quality night-time sleep, and anti-parkinsonian medication, such as dopamine agonists.</li></ul></li><li><strong>Aspiration pneumonia</strong> <ul><li>Pneumonia is a leading cause of death in the later stages of Parkinson's disease.</li></ul></li><li><strong>Pressure ulcers</strong><ul><li>Immobility in the later stages of disease and at the end of life puts people at risk of pressure ulcers. </li><li>Most pressure ulcers occur over bony prominences, but contractures of the limbs, together with immobility and altered body shape, may result in pressure ulcers appearing in more unusual locations.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">Chou, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">Nègre-Pagès et al, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">Beiske et al, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">SIGN, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">Zesiewicz, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">NICE, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">Valkovic, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">Kalia, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">NICE, 2017</a>]</p><!-- end field 4510bea8-03c0-46e4-8bb3-b6aa8d98fcdf --><!-- end item 80db9afe-cf14-4f8c-987b-1232d80c2a1a -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}